Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (331-340 of 566) with videos related to

Pageof 57
Sort By:
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Blood|November 9, 2011
Immunoglobulin D amyloidosis: a distinct entityMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaSagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Blood Cancer Journal|November 10, 2018
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myelomaM Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, et al.
Blood|June 25, 2014
Trends in survival of patients with primary plasma cell leukemia: a population-based analysisWilson I Gonsalves, S Vincent Rajkumar, Ronald S Go, et al.
American Journal of Hematology|May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of boneRahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Pageof 57

Showing results (331-340 of 566) with videos related to

Sort By:
Pageof 57
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Blood|November 9, 2011
Immunoglobulin D amyloidosis: a distinct entityMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaSagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.
Blood Cancer Journal|November 10, 2018
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myelomaM Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, et al.
Blood|June 25, 2014
Trends in survival of patients with primary plasma cell leukemia: a population-based analysisWilson I Gonsalves, S Vincent Rajkumar, Ronald S Go, et al.
American Journal of Hematology|May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of boneRahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Pageof 57